DESolveNx trial: Results of the new bioabsorbable platform

This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has shown equivalence to a Cypher stent. This device, also in vitro , showed a degradation time of one year and safety during post expansion, reaching 4.8 mm without fracturing. This is the first human trial and follow-up with different imaging modalities. We included 126 patients in 13 centers in Europe, New Zealand and Brazil with single de novo coronary lesions having a reference diameter between 2.75 and 3 mm and a length not exceeding 12 mm. The primary endpoint was late lumen loss at six months and secondary points (MACE) a combination of death, myocardial infarction related to the vesse, clinically justified revascularization, device thrombosis or evaluation by image parameters. 

Late lumen loss by quantitative angiography was 0.21 ± 0.34 mm with a binary restenosis rate of 3.4%. All restenosis were focal over device edges. We observed an increase in vessel size of 16.8% (p <.001) and an increased device area at six months of 15.7% (p <.001) confirmed by both IVUS and OCT. There was an OCT platform coverage of 98.6%. MACE was 3.25% without spotting device thrombosis. Lumen loss in diabetic patients was similar to non-diabetics.

Conclusion: The study DESolveNx showed the safety and efficacy of the new device.

Alexandre Abizaid, MD, PHD.
2013-05-21

Original title: First report of results from the pivotal DESolveNx trial: 6-month clinical and multimodality imaging results

More articles by this author

EnligHTN: treatment of refractory hypertension by catheterization

Lowering blood pressure with renal denervation has been demonstrated in previous studies but unfortunately there was not much data regarding the reduction of clinical...

SOURCE XT: Results of the latest generation of the Edwards valve

The first generation of the Edwards valve was stainless steel and bovine pericardium with a profile of 22 to 24 Fr for transfemoral access...

SCAAR: Heparin versus bivalirudin in patients with myocardial infarction without ST segment elevation.

We evaluated 41,537 patients admitted with myocardial infarction without ST elevation on the SCAAR register and who had not received IIBIIIB glycoprotein inhibitors and...

EUROMAX: Bivalirudin during transport to primary angioplasty

The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the use of heparin plus glycoprotein IIBIIIA. However,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...